Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • Analyst Insights & IR
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Alteogen (196170) Issued Advance Notice of Investment Warning Stock Designation; To Be Designated as Investment Caution Stock on Jan 6

Posted on January 3, 2025July 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Alteogen (196170) Issued Advance Notice of Investment Warning Stock Designation; To Be Designated as Investment Caution Stock on Jan 6

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-01-03

Disclosure Type: [Investment Caution] Advance Notice of Investment Warning Stock Designation

💡 3-Second Summary

Alteogen has received an ‘Advance Notice of Investment Warning Stock’ designation from the Korea Exchange due to a sharp stock price surge of over 200% compared to last year, and will be placed under the ‘Investment Caution’ status for one day on January 6.

📊 1. [Key Disclosure Content & Major Figures Summary]

  • Status & Timeline: Alteogen Common Stock; Due to the possibility of being designated as an Investment Warning Stock, it will be temporarily designated as an Investment Caution Stock for one day on January 6, 2025.
  • Reason for Advance Notice (As of January 3, 2025):
    • The closing price on January 3 skyrocketed by 200% or more compared to its closing price one year ago.
    • The trading concentration among the top 10 accounts with significant market influence met the designated surveillance criteria for 4 or more days during the last 15 trading days (fulfilling condition ③ of the super long-term increase and unfair trade conditions).
  • Final Investment Warning Designation Criteria: The stock will be finalized as an Investment Warning Stock on the following day if all of the following conditions are simultaneously met on any specific trading day (Review Date, T) between January 6 and January 17, 2025:
    1. The closing price on day T is 200% or more higher than the closing price one year ago.
    2. The closing price on day T is the highest closing price within the recent 15 trading days (including day T).
    3. The trading concentration among the top 10 accounts with high market influence meets the surveillance criteria for 4 or more days within the last 15 trading days.
  • Governing Regulation: Article 5-3 of the Market Surveillance Regulation and Article 3-3 of the Enforcement Rules of the same regulation.

📈 2. [Expert View: What This Disclosure Means for Investors]

  • Overheating Signal via Market Alert System: This represents the first step (‘Investment Caution’) of the KRX market alarm protocol and serves as a final preliminary buffer before graduating to an ‘Investment Warning’. It officially alerts the market that the short-term price momentum has been exceptionally rapid and that buying activity has been concentrated in a limited pool of accounts.
  • Potential Regulatory Risks Upon Status Upgrade: If the stock continues to rally and hits new 15-day closing highs between January 6 and January 17, it will immediately trigger the ‘Investment Warning Stock’ designation. This upgrade carries structural constraints, such as a complete ban on margin buying and requiring a 100% cash deposit, which may temporarily compress institutional and retail trading volumes.
  • Investor Assessment Guide: This disclosure is a technical market stabilization intervention driven by recent price mechanics, not an announcement regarding structural shifts in earnings, partnerships, or bio-pipeline updates. Investors should closely monitor whether the stock breaks above its recent peaks during the evaluation window ending January 17, and utilize this warning as a metric to evaluate short-term volatility risks rather than chasing the momentum aggressively.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s relentless market run has officially triggered the regulatory radars at the Korea Exchange. With the stock climbing over 200% within a year and trading volumes concentrating heavily within a handful of prominent accounts, market watchdogs are preparing to pull out a formal warning card. While Monday (January 6) will see the stock trade under a lighter ‘Investment Caution’ label, any immediate failure to cool down—specifically breaking out to new closing highs before January 17—will send it straight into an ‘Investment Warning’ lockup. This higher status completely cuts off credit financing and forces 100% cash terms on buyers. Because regulatory frictions frequently induce erratic swing hazards in overextended charts, prioritizing capital defense over aggressive trend-chasing seems highly prudent.

📢 Disclaimer & Source Information

Source: This content was structured and newly written based on the official submitted data from the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Isu Petasys (007660) Maintains “Unconfirmed” Stance on Scrapping ‘Jeio Acquisition’ Rumors; Prolonged Wait-and-See Amid Governance Storm
Next Post: [Disclosure] HANMI Semiconductor (042700) Launches New Year US NDR via ‘CES 2025’: Pitching HBM4 Hybrid Bonding Roadmap to Wall Street Big Money

Related Posts

[Disclosure] Alteogen (196170) Scores Huge Win: Eylea Biosimilar ‘Eyzanfy’ Secures Official MFDS Marketing Approval in South Korea Disclosures
[Disclosure] Alteogen (196170) Receives Advance Notice of Unfaithful Disclosure Corporation Designation Following Two Cases of Mergers and Acquisition Cancellations Disclosures
[Disclosure] Alteogen (196170) Hits Jackpot: Signs KRW 867.5B Exclusive License Deal with Global Big Pharma Biogen for ALT-B4 Bio & Healthcare
[Disclosure] Alteogen (196170) Approves ‘Amendments to Articles of Incorporation’ at Extraordinary General Meeting of Shareholders Disclosures
[Disclosure] Alteogen(196170) Reports KRW 114.7B Operating Profit for 2025… A Massive 274.8% YoY Surge Disclosures
[Disclosure] Alteogen (196170) Clarifies Media Report on ‘KRW 200B RCPS Issuance and Shinhan Securities as Lead Manager’: “Under Consideration But Unconfirmed; No Lead Manager Contract Signed” Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hana Micron (067310) Lifted from Investment Warning Stock Status; Reclassified to Investment Caution on June 9 with Re-designation WarningJuly 8, 2026
  • [Discount Reversal via ADR Listing and Entry into an HBM-Led Super Cycle: SK hynix 000660]July 7, 2026
  • [Discount Narrowing via ADR Listing Momentum and Capital Allocation Diversification: SK Square 402340]July 7, 2026
  • Gaon Cable (000500): Structural Re-rating Driven by North American Infrastructure Expansion and AI Data Center Demand ShocksJuly 7, 2026
  • Hugel (145020): Passing the Trough with Q2 Earnings Surprise and Accelerated U.S. Direct Sales DeploymentJuly 7, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme